Another Chinese 3D Printer drug product receives FDA trial approval

The emerging technology drug 3D Printer is constantly making breakthroughs. On May 12, the “Drug 3D Printer Industry Report” report released by the consulting agency Frost & Sullivan showed that several 3D Printer drug INDs (clinical trial approvals) have been approved to enter the clinical stage.In the future, as more 3D Printer drugs are commercialized, it will provide better medication options for patients.

The latest milestone in the field of 3D Printer pharmaceuticals comes from Nanjing Triastek Pharmaceutical Technology Co., Ltd. (“Triastek” for short, English name Triastek). Recently, Triassic announced that its self-developed 3D Printer drug product T20 has been approved by the US FDA for clinical trials. This is the second IND approved by the FDA for Triassic, and the third 3D Printer drug product in the world to enter the registration application stage.

For a long time, the drug 3D Printer technology can be applied to the field of solid preparation dominated by small molecule drugs. In recent years, with the rapid growth of the small molecule drug market, drug 3D Printer technology is also accelerating its expansion and application.

According to Frost & Sullivan data, from 2016 to 2019, the global small molecule drug market size increased from US$932.8 billion to US$1,038 billion, and the Chinese market size increased from RMB 722.6 billion to RMB 819 billion . The global market size is expected to grow to US$1,181.3 billion in 2025, and the Chinese market size to grow to RMB 975.2 billion in 2025.

According to Frost & Sullivan, the Drug 3D Printer transforms the underlying logic of pharmaceuticals and shows great commercial potential in both the directions of scale up and personalized pharmaceuticals. Compared to traditional pharmaceutical processes, Frost & Sullivan noted in the report that 3D printers are highly flexible, and the production process is digital and continuous. It has the potential to transform the way drugs are currently designed, manufactured and used.

The above report predicts that the pharmaceutical 3D Printer industry will prioritize commercialization in the direction of large-scale production. In the future, with the active exploration of the guiding principles and regulations of personalized medicine, the application in this direction will also expand rapidly.